208 related articles for article (PubMed ID: 18959781)
1. Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures.
Daigeler A; Klein-Hitpass L; Chromik MA; Müller O; Hauser J; Homann HH; Steinau HU; Lehnhardt M
BMC Cancer; 2008 Oct; 8():313. PubMed ID: 18959781
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells.
Harati K; Daigeler A; Hirsch T; Jacobsen F; Behr B; Wallner C; Lehnhardt M; Becerikli M
Int J Mol Med; 2016 Jun; 37(6):1535-41. PubMed ID: 27082154
[TBL] [Abstract][Full Text] [Related]
3. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
4. Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.
Vay C; Schlünder PM; Dizdar L; Esposito I; Ghadimi MPH; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):633-645. PubMed ID: 34860309
[TBL] [Abstract][Full Text] [Related]
5. Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis.
Song JH; Choi CH; Yeom HJ; Hwang SY; Kim TS
Life Sci; 2006 Jun; 79(2):193-202. PubMed ID: 16458935
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.
Gits CM; van Kuijk PF; Jonkers MB; Boersma AW; Smid M; van Ijcken WF; Coindre JM; Chibon F; Verhoef C; Mathijssen RH; den Bakker MA; Verweij J; Sleijfer S; Wiemer EA
Int J Cancer; 2014 Jul; 135(2):348-61. PubMed ID: 24375455
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
9. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.
Lehnhardt M; Klein-Hitpass L; Kuhnen C; Homann HH; Daigeler A; Steinau HU; Roehrs S; Schnoor L; Steinstraesser L; Mueller O
BMC Cancer; 2005 Jul; 5():74. PubMed ID: 16001973
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.
Gobble RM; Qin LX; Brill ER; Angeles CV; Ugras S; O'Connor RB; Moraco NH; Decarolis PL; Antonescu C; Singer S
Cancer Res; 2011 Apr; 71(7):2697-705. PubMed ID: 21335544
[TBL] [Abstract][Full Text] [Related]
11. Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Sawicka A; Węgrzyn P; Krzanik S; Górka A; Drożniak J; Augustyniak E; Kowalczyk A; Rokita H
Acta Biochim Pol; 2015; 62(3):423-33. PubMed ID: 26284262
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
[TBL] [Abstract][Full Text] [Related]
13. Cell-type-specific responses to chemotherapeutics in breast cancer.
Troester MA; Hoadley KA; Sørlie T; Herbert BS; Børresen-Dale AL; Lønning PE; Shay JW; Kaufmann WK; Perou CM
Cancer Res; 2004 Jun; 64(12):4218-26. PubMed ID: 15205334
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression.
Notarbartolo M; Poma P; Perri D; Dusonchet L; Cervello M; D'Alessandro N
Cancer Lett; 2005 Jun; 224(1):53-65. PubMed ID: 15911101
[TBL] [Abstract][Full Text] [Related]
15. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines.
Stravopodis DJ; Karkoulis PK; Konstantakou EG; Melachroinou S; Lampidonis AD; Anastasiou D; Kachrilas S; Messini-Nikolaki N; Papassideri IS; Aravantinos G; Margaritis LH; Voutsinas GE
Int J Oncol; 2009 Jan; 34(1):137-60. PubMed ID: 19082486
[TBL] [Abstract][Full Text] [Related]
16. Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin.
Hao H; Dong YB; Bowling MT; Zhou HS; McMasters KM
Anticancer Res; 2006; 26(3A):1947-56. PubMed ID: 16827129
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
Jia B; Choy E; Cote G; Harmon D; Ye S; Kan Q; Mankin H; Hornicek F; Duan Z
Cancer Lett; 2014 Jan; 342(1):104-12. PubMed ID: 24007862
[TBL] [Abstract][Full Text] [Related]
18. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
Singer S; Socci ND; Ambrosini G; Sambol E; Decarolis P; Wu Y; O'Connor R; Maki R; Viale A; Sander C; Schwartz GK; Antonescu CR
Cancer Res; 2007 Jul; 67(14):6626-36. PubMed ID: 17638873
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS-CHOP transcript.
De Cecco L; Gariboldi M; Reid JF; Lagonigro MS; Tamborini E; Albertini V; Staurengo S; Pilotti S; Pierotti MA
Histopathology; 2005 Mar; 46(3):334-41. PubMed ID: 15720420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
